In response to a spate of pharmaceutical mergers, several antitrust regulators and enforcement agencies from the U.S. and Europe are forming a working group to better understand the impact these deals have on prescription drug pricing and competition.
The goal is to update the approach taken to analyzing potential economic harms that a merger may cause; the extent to which a merger may thwart R&D innovation; evidence needed to challenge a merger; and how other conduct in which companies have engaged — such as instances of pricing fixing — be considered when reviewing a deal.
About the Author Reprints
